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ABSTRACT  
Small volume, high surface area and protective fibulas scaffold of collagen modular 
microenvironment improves cell viability and proliferation. Therefore, the ability to 
produce collagen modular microenvironment accurately and reliably is of most 
importance to the advancement of tissue engineering. Currently, no such fabrication 
technique exists due to the inherent fragility of collagen. Herein, we report the very first 
platform that addresses such challenges. Pneumatic actuated soft micro mold (PASMO) 
composes asymmetric structure, which performs different mechanical properties. 
PASMO device is classified as particles’ template(top layer), air channel layer(middle 
layer) and resistance(bottom layer).  The major deformation of PASMO is assigned to 
particles’ template layer because the mechanical property of particles’ template is less 
than resistance layer. Therefore, the deformation would form on particles’ template to 
expand and extract microparticles from PASMO device after increasing inner pressure. 
Soft micro mold with pneumatic extraction actuator not only can produce arbitrary 
shapes of collagen microstructures precisely but also can encapsulate cells inside without 
causing damage during the extraction process. 
MDA-MB-231-GFP encapsulated in collagen microcubes can fully stretch and 
survive well. Moreover, MDA-MB-231-GFP in collagen microcubes can sense the 
treatment of Paclitaxel and the size of microcubes changed as following the different 
concentration of Paclitaxel due to the inhibition of cellar division. Furthermore, creating 
cancer microenvironment can efficiently localize cancer cells at the specific location so 
that it minimizes the varieties of experiments.  
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Another application is for cell therapy, like beta cells encapsulation for creating 
artificial islet. Artificial islets are micro-disk can secrete insulin based on the stimulation 
of glucose from the surrounding. Blood vessels can successfully form around the 
implanted artificial islets. This formation of the blood vessel for subcutaneous 
transplantation not only can regulate the level of glucose in blood but also can simplify 
surgery to avoid the risk. For multiple locations of implanted artificial islets clusters, 
blood vessels can also form connections between these two groups. 
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NOMENCLATURE 
2D two-dimensional 
3D three-dimensional  
ECM extracellular matrix 
HA hyaluronic acid 
PEG poly(ethylene) glycol 
PEGDA poly(ethylene) glycol diacylate 
RGD arginylglycylaspartic acid 
DNA deoxyribonucleic acid 
UV ultraviolet 
Gly Glycine 
Pro Proline 
Lys Lysine 
Asp Aspartic acid 
Hyp Hydroxyproline 
FAK focal adhesion kinase 
EMT epithelial–mesenchymal transition 
PASMO pneumatic actuated soft micromold 
cPASMO circular pneumatic actuated soft micromold 
SHG secondary harmonic generation 
GFP green fluorescent protein 
MDR multidrug resistance derived 
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MCF-7 Human Breast Cancer Cell Line 
T4-2 Human Breast Cancer Cell Line 
MDA-MB-231 Breast Cancer Cell Line 
U2OS Osteosarcoma Cell Line 
HMT-3522 Mutated from normal cell line 
DMEM Dulbecco’s Minimal Essential Medium 
FBS Fetal bovine serum 
AsPC1-Luc Pancreatic cells line expressed luciferase 
BMP4  Bone morphogenetic protein 4 
FGF Fibroblast Growth Factor 
EGFR Epidermal growth factor receptor 
IBMIR instant blood-mediated inflammatory reaction 
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1. INTRODUCTION- 3D MICROENVIRONMENT

 
1.1 2D and 3D Cell Culture 
In vivo study is the method to simulate the human response under different stimuli 
from different treatment, especially for drug screening.
1,2
 However, in vivo study hinders 
the screening rate of drug development because of time-consuming process. Time-
consuming process comes not only from complicated metabolic processes of living 
organism but also from discovering and isolating the meaningfully biological 
information from individual variability. In vitro study is developed as a crucial tool to 
speed up and simplify the screening process for realizing biological functions under 
different stimuli. In vitro study started from 1950s, and it stands for culturing 
microorganism, cells, or biological molecular outside their normal biological 
surrounding. In 1970s, NCI funded study evaluated the technique, which develops 
colony assay to grow fresh human patient cells in soft agar for drug screening.
3
 They re-
tested over 79 compounds of anticancer drugs, which are inactive in the in vivo drug 
screening, especially for breast, colorectal, kidney, lung, melanoma, and ovarian. 
However, soft agar assays has limitation for plating efficiency because of lacking of 
constant supply of fresh patient samples, even the efficiency is 70-80%. As a result, this 
assay is still considered as impractical drug screening tool.
4
 To improve screening 
efficiency, cancer research relies on two-dimensional cell cultures (2D culture).
5,6
 2D 
culture is the process that we culture cell on petri dish or culture flask. Cancer cell line is 
isolated from patients as source and these cells are transferred on petri dish, which 
                                                 

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contains culture media as nutrient. In particular, cells are attached onto rigid and flat 
substrates, which force them to polarize and increase their exchange area for culturing. 
However, the biological function in 2D culture model is eliminated due to abnormal 
morphology of cells.
7,8
 Abnormal cell morphology can influence many cellular process 
including cell proliferation, differentiation, apoptosis, and gene and protein expression.
9
 
A variety of cell lines indicates that cell proliferation rate is significantly different in 2D 
and 3D culture.
10-15
 For example, osteosarcoma cell line U2OS or breast adenocarcinoma 
cell line MCF-7 in 3D type I collagen microenvironment have reduced proliferation rate 
compare to 2D culture model.
12
 The main reason is that transcriptional and translational 
levels are changed. When cells are isolated out of their natural microenvironment, the 
cells would adopt the new microenvironment by their biological functions. The obvious 
cellular function is cell growth and proliferation. Approximately 30% of genes are 
differently expressed in 2D culture, especially interfering cell proliferation. This support 
the observation of cell proliferation in 2D culture is faster than in 3D culture.
16
 Moreover, 
the signal transduction pathway would also be interrupted and then the differentiation 
and apoptosis would be influenced. For example, tenascin C can regulate FGF2 and 
BMP4 signaling pathway, both which are related with the differentiation of neural stem 
cells.
17
 These two pathway cannot be observed and monitored in 2D culture because of 
lacking of cell-cell or cell-matrix interaction.
18
 Eventually, 2D culture is not a proper 
way to use as a tool for further biological application. A variety of researches presents 
that 2D culture would mislead the sensitivity of drugs.
19
 In one study, human breast 
cancer cell line (T4-2) isolated and mutated from normal cell line (HMT-3522) cultured 
 3 
 
in 3D collagen model. The epidermal growth factor receptor (EGFR) antibody were 
treated with encapsulated T4-2 and the down-regulation between EGFR and β1-integrin 
can be observed. On the other hand, down-regulation between EGFR and β1-integrin in 
2D culture cannot be distinguished after treating EGFR antibody because of no cell-cell 
interaction.
19
 Another misleading of bio-function in 2D culture is multidrug resistance. A 
human breast cancer cell line (MCF-7) and its multidrug resistance derived cell line 
(MDR-MCF-7) were cultured in 2D and 3D microenvironment, respectively.  Both types 
of cancer cells were reduced the proliferation after treating anti-cancer drug doxorubicin 
either in 3D culture or in 2D culture. However, MCF-7 reduced the sensitivity of 
doxorubicin in 3D culture and MDR-MCF-7 presented no response to anti-drug 
treatment. The main reason is that 2D culture is the monolayer culture, which can expose 
large area to sense the surrounding stimuli and eliminate the physical barrier. As a result, 
the sensitivity of drug or surrounding stimuli in 2D culture is more sensitive than in 3D 
culture.
20-22
 Figure 1 shows the relationship of biological function in 2D and 3D culture. 
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1.2 3D Cell Culture 
The conventional 2D cell culture is used to help us realize the complex cellular 
physiology, like how cells have responds to surrounding stimuli. While 3D cell culture is 
designed as a tool to mimic in vivo condition. Figure 2 is the schematic diagram of 3D 
cell culture. 3D cell culture is to encapsulate cells in extracellular matrix (ECM)  within 
3D structure instead of 2D monolayer cell sheet. The target cells are mixed and 
encapsulated in ECM, which contains porous structure. oxygen, nutrient, or surrounding 
stimuli is allowed to diffuse into 3D microenvironment through porous structure. After 
metabolism, the product or waste can also diffuse out of microcapsule. 3D 
microenvironment can be used as a microcapsule to implant it into animal for monitoring 
the biological function in animal model because ECM plays a crucial role to resist of 
attacking from immune cells. Therefore, the immunoresponse can be eliminated and the 
immunosuppressant is not necessary to apply in animal experiment.  Some 
immunosuppressant would affect the cell function and even lose biological function. For 
example, cyclosporine can effectively inhibit the immunoresponse, however, 
cyclosporine is highly toxic for liver, kidney, and pancreatic beta cells. As a result, there 
are more irregular biological response would be observed in order to mislead the cellular 
function.
23
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Figure 1 Comparison between 2D and 3D cell culture.  2D cell culture presents abnormal cell morphology 
and lacks of cell-cell or cell-matrix interaction so that the cellular function would be interfered 
 
 
 
 
Figure 2 Schematic diagram for 3D microenvironment. Oxygen and nutrient can be allowed to diffuse 
inside the 3D microenvironment. While, the metabolic waste can also diffuse out due to porous structure. 
Moreover, microenvironment is also a good barrier for immune cells to reduce the immune response 
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1.3 Hydrogel Material 
The properties of extracellular matrix play important roles for biologic function 
because it would generate different cell-cell or cell-matrix interaction. Then, the signal 
transduction pathway would be triggered as different pathway based on cell-matrix 
interaction.
24
 In cancer research, the mechanical properties of ECM would activate 
different progression of cancer development. For example, stiffer matrix can enhance 
cell growth, focal adhesion, integrin clustering and matrix invasion. Cells are able to 
sense the matrix stiffness and activate the mechanical signal transduction pathway, 
which is known as mechano-transduction. This pathway has been influenced cell 
proliferation and differentiation.
25-27
 
Polymeric hydrogels are composed by hydrophilic and porous structure, which can 
easily to allow water, oxygen, and nutrient to diffuse and exchange in this network. 
Hydrophilic network is composed by controlling physical or chemical condition to make 
cross-linking reaction. Therefore, the physical or chemical properties of polymeric 
hydrogel, like mechanical properties, swelling ratio, degradation rate, 3D architecture, 
and bioactivity, can be adjusted easily by the level of cross-linking. 
Polymeric hydrogels can be classified as natural and synthetic hydrogel. Natural 
hydrogel, like collagen,
28
 hyaluronic acid (HA),
29
 alginate,
10
 chitosan,
30
 silk fibrils,
31
 
agarose,
32
and cellulose,
33
 is isolated from organism. Since these materials are extracted 
from natural source, they have excellent biocompatibility, bioactivity and 
biodegradability, and low immunogenicity for artificial ECM. However, they still have 
some disadvantages for cell encapsulation. For example, alginate has good bioactivity 
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for cell viability, but alginate cannot be used as cell microcapsules because of 
inflammatory response. Otterlei et al. found that alginate microcapsule would induce and 
active the human monocytes and then trigger inflammatory response when the 
accumulation of monocytes is formed.
34-35
 Moreover, Soon-Shiong et al. also noticed 
that the cell morphology in alginate is abnormal growth.
36
 Chokkalingam et al. used 
agarose to encapsulate and immobilize cell in microcapsule. The immunoresponse is not 
much obvious than alginate but the solidification of agarose needs to heat up for melting 
then mixed with cells for encapsulation. The process is hard to control and the 
reproducibility for encapsulating is lower than other material. Moreover, increasing 
temperature sometimes kills cells because the operating temperature is over the tolerance 
for cells.
32
 Another disadvantage for natural ECM is weak mechanical properties. Tan et 
al. used chitosan as the target material for cell encapsulation. The structure of chitosan 
microcapsule is soft and unstable. Therefore, chitosan need to mix with collagen to 
stabilize the structure and improve the mechanical properties.
37
  
To overcome these shortcoming of natural ECM, researchers develop synthetic 
polymer as the material of ECM due to their flexible chemistry and biophysical 
properties. The quality of synthetic polymer is consistency because the batch-to-batch 
process is easy to control and reproduce. Poly(ethylene glycol) (PEG)-based hydrogel is 
an outstanding example for synthetic hydrogel. PEG not only has excellent mechanical 
property but also has well-tuned structure through modifying chemical composition. 
Moreover, microfluidic system and photolithography process can be integrated into 
producing PEG hydrogel for mass production.
38
 Moreover, bioinert is also the signature 
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property for synthetic hydrogel due to no adhesion site for attaching.
39
 However, bioinert 
is not suitable for cell encapsulation because of no adhesion site for target cells. 
Therefore, some DNA sequences are used to modify the backbone of synthetic polymer. 
Arginine-glycine-aspartate (RGD), which can be found in collagen, is the most common 
DNA sequence to improve the cell adhesion.
40-42
 Moreover, PEG-peptide can also 
activate the inflammatory reaction so that anti-inflammatory DNA sequence is needed to 
introduce for modifying the backbone of PEG.
42
 Another disadvantage of PEG is that the 
cross-linking of PEG is constructed by UV cross-linking. PEG precursor solution needs 
to mix with photoinitiator and then expose under UV light for cross-linking. Radical and 
chemical reagent would induce toxicity of cells, even kill cells during the cross-linking 
process. Table 1 shows the arrangement of advantage and disadvantage for natural and 
synthetic hydrogel.  
Collagen is the most common materials for constructing extracellular matrix because 
it is abundant protein in human. Therefore, the biocapability and biocompatibility are the 
innate properties for collagen. Collagen fibers are constructed three polypeptide α-chains 
through entanglement of each polypeptide.
52
 Figure 3 presents the schematic diagram for 
collagen fiber. Each polypeptide chain is composed by Gly-X-Y triplet repeatedly. Gly-
X-Y triplet assists the interaction between three polypeptide through hydrogen bond. 
Collagen fiber can be classified as homotrimeric or heterotrimetic triple helices based on 
the composition of triplet. Homotrimeric collagen is constructed by repeated triplet, Gly-
X-Y, to form fibrous structure, while, heterotrimeric collagen is composed by different 
triplets in fiber. Gauba and Hartgerink observed that the assemble heterotrimeric 
 9 
 
collagen is combined by the mixture (Pro-Lys-Gly)10/(AspHypGly)10/(ProHypGly)10 for 
1:1:1 ratio.
53
 
 
Table 1 Advantages and disadvantages of external cellular matrix using natural and synthetic hydrogel  
Hydrogel 
Advantage for cell 
encapsulation 
Disadvantage for cell encapsulation 
Natural 
Alginate 
1. Abundance 
2. Excellent 
biocompability 
3. Biodegradable 
4. Low immunogenicity 
 
1. Inflammatory response43,44 
2. Abnormal cell growth45 
Chitosan 
Weak mechanical property, Need 
to blend with other polymer to 
improve, like collagen
46,47
 
Agarose 
Temperature for solidification is 
high so that it’s difficult to operate 
for encapsulating cells.
48
 
Synthetic- PEGDA 
1. Good mechanical 
properties 
2. Suitable for micro 
fabrication 
3. Bioinert (lower protein 
absorption) 
4. Well-tuned structure 
function relations 
 
1. No Adhesion site, Need to 
functionalize PEGDA with 
DNA sequence
49,50
 
2. Inflammatory reaction, Need to 
functionalized anti-flammatory 
DNA sequence
50
 
3. Radical and heavy metal 
polymerization will induce 
cytotoxicity
51
 
 
Collagen fiber in human is cross-linking via hydroxylation at posttranslational 
modifications.
54
 Numerous enzymes, like hydroxylases, collagen glycosyltransferases, 
peptidyl cis-trans isomerase and protein disulphide isomerase, assist the cross-linking, 
modification, folding in human in order to present biological function.
55 
According to 
different modifications and functions of collagen, collagen can be categorized as 28 
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different collagens at least. The distribution of each type of collagen is shown in Table 2. 
Among these collagens, collagen type I is extremely applied in fabricating 3D 
microenvironment without imperfection and dominant in tissue. Other collagens would 
interrupt the triple helix structure as a result in blocking cell adhesion and signal 
transduction.
56
 
 
 
Figure 3 Collagen fiber structure. Collagen fiber is formed by triple helix collagen fiber in which the 
backbone of each collagen molecules is composed by Gly-X-Y. X and Y are any amino-acid, while 
Proline (Pro), Lysine  (Lys), Asparitic acid (Asp), and Hydroporline (Hyp) are most common component 
for collagen molecules. (Reprinted from Ref. 53) 
 
Collagen-based ECM is a good tool to mimic the progression for cancer study 
because large amounts of cancer properties are related to collagen fiber, such as 
migration and invasion.
57
 Table 3 presents the researches using collagen-based ECM to 
realize the cancer properties. Therefore, owing to developing drug and treatment for 
patient, the interaction between cancer cell and matrix are important tools to recognize. 
Tumorigenesis is a multiple process characterized by (1) Limitless cellular proliferation 
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(2) cancer angiogenesis (3) invasion and metastasis. For example, cancer cell 
proliferation depends on the activation of the integrin β1, which can activate the FAK 
pathway. Brian et al. discovered that culturing MCF-7 in 3D collagen microenvironment 
can mimic and match in vivo model, especially for cell proliferation, cell viability, 
migration, and invasion. Moreover, they also used collagen-based 3D microenvironment 
to use as a validation platform for drug scanning.
58-59
  
Angiogenesis is the formation of new capillary tube for obtaining oxygen and 
nutrient after metastasis. Kimlin et al.
60
 discovered that co-culture of stromal cells and 
cancer cells in the same collagen-based 3D microenvironment can structure capillary-
like microvasculature around cancer cells. This proves that the relationship between 
angiogenesis and interaction of cancer cells, collagen fiber and stromal cells.  The 
mechanism of metastasis is hard to monitor because it occurred following circulation 
system. Therefore, collagen-based 3D microenvironment is used as tissue, and 
microfluidic system is designed as artificial blood stream. This integration under 
continuous flow enables to mimic the circulation system and realize EMT process during 
intravasation and metastasis.
61-63
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Table 2 The distribution of different collagen types presents in the human body. (Rewritten from Ref. 54) 
 
Type Class Distribution 
I Fibril 
Abundant and widespread in non-cartilaginous connective tissue: dermis, bone, tendon, 
ligament 
II Fibril Cartilage, vitreous 
III Fibril Co-distribution with collagen I: skin, blood, vessels, intestine 
IV Network Basement Membrane (BM) 
V Fibril Widespread and co-distribution with collagen I: bone, dermis, cornea, placenta 
VI Network Widespread: muscle, bone, cartilage, cornea, vitreous 
VII FACIT Dermis, bladder 
VIII Network Widespread: dermis, brain, heart, kidney 
IX FACIT Co-distribution with collagen II: cartilage, cornea, vitreous 
X Network Hypertrophic cartilage 
XI Fibril Co-distribution with collagen II: cartilage, intervertebral disc 
XII FACIT Co-distribution with collagen I: dermis, tendon 
XIII MACIT Endothelial cells, dermis, eye, heart 
XIV FACIT Widespread and co-distribution with collagen I: bone, dermis, cartilage 
XV MULTIPLEXIN Located between collagen fibrils that are close to BM, capillaries, testis, kidney, heart. 
XVI FACIT Integrated into collagen fibrils and fibrillin-1 microfibrils, dermis, kidney 
XVII MACIT Hemidesmosomes in epithelia 
XVIII MULTIPLEXIN Associated with BM, liver 
XIX FACIT Rate, localized to BM 
XX FACIT Widespread: cornea (chick) 
XXI FACIT Widespread: stomach, kidney 
XXII FACIT Tissue Junctions 
XXIII MACIT Limited distribution: heart, retina 
XXIV Fibril Shares sequence homology with the fibril-forming collagens: bone, cornea 
XXV MACIT Brain, heart and testis 
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Table 3 Collagen-based ECM used in cancer research  
Crosslinking 
method 
Cell source 
Engineered  
3D tissue 
models 
Application Reference 
Thermogelation 
NHEKs, NHDFS,  
SCC-12B and 
SCC13 
Skin tissues 
carcinoma 
progression 
62 
Thermogelation ADSCs Skin tissues 
Evalulating 
vasculatizerd skin 
63 
Thermogelation 
MCF-7, MYO 
1089, 
 HB4a, and 
HMFU19 
Breast Cancer 
Breast cancer 
progression 
59 
Thermogelation MCF-10A Breast Cancer 
Breast cancer 
proliferation 
65 
3D collagen 
lattice 
MDA-MB-231 Breast Cancer 
ECM degradation 
for Cancer 
66 
Thermogelation MDA-MB-231 Breast Cancer Blood Circulation 61 
Thermogelation HMVEC Vascular  human angiogenesis 60 
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1.4 Methodology for generating 3D microenvironment 
Figure 4 shows the listed methodology for generating 3D microenvironment. 3D 
microenvironment can be created by hanging-drop,
68-71
 bio-printing,
72
 microfluidic 
device,
73
 continuous flow lithography
74
 and magnetic assembly levitation
75
. Hanging-
drop is a good tool to make 3D microenvironment, especially for cell spheroid. Hanging-
drop use surface tension around tiny holes to form droplet. Then, the suspended cells in 
droplet would force to aggregate and to form cell spheroid naturally.
68
 Another method 
is for using pipetting to generate droplet manually.
69-70
 However, hanging-drop approach 
is time consuming and labor-intensive process so that the production efficiency is 
relative low. Furthermore, the size distribution of cell spheroid is wide and the cell 
densities are not uniform.
71
 Therefore, Hanging-drop system is not for wide-spreading.  
Bio-printing is a method to generate controllable process to eliminate the board variety 
of size uniformity. It integrated a simple, robust, and reproducible valve-based generator 
to print droplet out through adjusting voltage
76
 or light.
77-79
 Bio-printing is automatic and 
high-throuput system to generate 160 droplets per second. Compare to hanging-drop 
approach, the duration of preparation can be reduced as 600-fold.
72
 However, cells 
cannot tolerate high temperature and stress during producing droplet via voltage or light 
so that the cell viability would be inhibited. Hung et al. designed microfluidic device to 
generate uniform 3D microspheroid for high throughput production.
73
 Microfluidic 
device is design as flow focused microchannel. They use inertial force to make droplet in 
oil-to-water system. The size of microparticles are around 200 to 300µm. Microfluidic 
device can provide high-throughput of producing microparticles within uniform particle 
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size, however, oil phase around surface of microparticles would interrupt the function of 
encapsulated cells. On the other hand, oil phase would inhibit the cell function during 
the production of microspheres. Normally, 3D microenvironment has an issue for 
Insufficient diffusion of oxygen and nutrient would lead cells located at center part 
perform hypoxia and necrosis because of no vascular system. To overcome this problem, 
we can change the morphology of microparticles to improve the surface area to volume 
ratio. Higher surface area to volume ratio would enhance the diffusion rate of nutrient. 
The surface area to volume ratio for sphere is lower than the cube one. However, 
hanging-drop, bio-printing, and microfluidic device have limitation for producing non-
spherical microparticles. Magnetic assembly levitation was also designed to produce 
non-spherical microenvironment.
75,80
 Magnetic nanoparticles are encapsulated in 
polymer based microenvironment. Then, the formation of microparticles can be 
assembled into any shape of micro-cluster through controlling magnetic field and 
direction. However, the possible interaction between nanoparticles and cells would 
interfere the cell viability and its biological function. If the alternately current is applied, 
the local magnetic hyperthermia could also affect the cellular function and leads to 
destroy the structure of microenvironment.
81
 Dendukuri et al. developed continuous flow 
lithography to make non-spherical micro-hydrogel.
74
 They integrated the concept of 
microfluidic device and photolithography to make non-spherical microparticles. The 
polymer precursor, PEG solution, mixed with photoinitiator and then introduced into 
microfluidic device. Photomask within particles’ pattern was placed underneath of 
microfluidic channel. Once the polymer precursor mixture passed through the exposing 
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area, solidification of PEG would occur at open area via photo-crosslinking. These PEG 
particles can be removed by flow after removing UV light. This system can be also used 
for mass production of non-spherical microparticles but the limitation is for material. 
Continuous flow lithography is integrated microfluidic device and photolithography. 
Therefore, continuous flow lithography is not allowed to synthesize non-photoinduced 
cross-linked polymer, like collagen. 
 
 
Figure 4 Methodology for making cell encapsulated capsule. Left side presents the method, hanging drop, 
bio-printing, and microfluidic system to generate spheroid capsule and right side shows the method, 
continuous flow lithography and magnetic assembly levitation to generate non-spheroid capsule 
 
1.5 Morphology of Microenvironment 
Based on the proliferation in 3D microenvironment, we can also distinguish as three 
zones, proliferating zone, quiescent viable cell zone, and necrotic zone, from outer layer 
to center of microenvironment.
83
 Figure 5 presents the schematic diagram of typical zone 
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of cell proliferation in 3D microenvironment. These three zones are determined by the 
diffusion range of oxygen and nutrient. The diffusion limitation of about 150-200µm to 
many molecules, particularly for oxygen. Insufficient mass transportation leads to the 
accumulation of metabolic waste in the core so that a 3D microenvironment within 
500µm size would display a layer-by-layer structure, which is called necrosis core, 
quiescent viable are and proliferation zone.
84
 The morphology can be used to improve 
the diffusion efficiency through changing the morphology of microenvironment. The 
diffusion rate is proportional to the surface area. On the other hands, higher surface area 
can trigger faster diffusion rate.  
 
 
Figure 5 Schematic diagram 3D environment. 3D environment composed proliferating, quiescent and 
necrotic zone based on the mass diffusion of molecules. Proliferation zone is the region to perform low 
resistance of diffusion, while the necrotic core stands for the region presents high resistance of diffusion. 
(Reprinted from Ref. 84) 
 
Table 4 is the comparison between different morphologies of particles. We collect 
sphere, triangle prism, and cubic particles for comparing their S/V ratio. The S/V ratio of 
spherical particles performs the lowest S/V ratio, which has 4.836, while the S/V ratio of 
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cubic particles presents 6. Except triangle prism and cubic particles, there is comparison 
between different morphologies shown in Figure 6 and they also mentioned the spherical 
particles have the lowest S/V ratio when the volume of each particles maintains constant.  
This result indicates that the diffusion rate can be improved through designing and 
creating different morphologies of particles. On the other hand, the necrotic core can be 
minimized and even eliminated by changing the particles’ morphology. In this 
dissertation, we developed a device, called pneumatic actuated soft micromold 
(PASMO) device, which integrated pneumatic actuator and particles’ template to create 
3D cellular microenvironment. PASMO provides a controllable and gentle process to 
generate and extract cellular microenvironment within different shapes and sizes. 
Table 4 Surface-to-volume ratios of sphere, triangle prism, and cube 
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Figure 6 Surface area-to-volume ratio for different particles’ shape. The spherical shape is more stable but 
it performed the lowest surface area-to volume ratio. This result interfere the diffusion of nutrients  
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2. DESIGN PNEUMATIC ACTUATED SOFT MICROMOLD

 
2.1 Design of pneumatic actuated soft micromold (PASMO) 
In this dissertation, we develop a system, pneumatic actuator soft micromold 
(PASMO) to produce non-spherical collagen microparticles for 3D environment. This 
system integrated soft microwell and pneumatic actuator. Pneumatic actuated soft 
micromold is inspired from Whiteside’s group.85 pneumatic actuator is composed two 
layers: top layer contained channel is for softer material and bottom layer is for stiffer 
material. In the beginning, the actuator does not deform due to the pressure difference 
between inside and outside is equal. Once the air is injected into air channel, the inside 
pressure is larger than atmosphere and then top layer would deform. However, the 
deformation of bottom layer is less than top layer because the mechanical properties are 
higher than top layer. Therefore, the obvious deformation is presented on top layer. 
Based on this result, we design three layers structure as a platform for extracting 
microparticles. The structure of pneumatic actuator soft micromold is constructed as 
three layers. Top layer is for soft microwells in order to making microparitcles and the 
middle layer is the air channel for actuation. The bottom layer is the stiffer material, 
which is used as resistance against the deformation from middle layer.  
Figure 7 shows the strategy for actuation through pneumatic force and Figure 8 
summarizes the process of extracting collagen microparticles from pneumatic actuated 
soft micro-molds. 3D collagen microparticles extraction process consists of five steps.  
 
                                                 

 Reprinted with permission from SOFT ROBOTICS, Year 2017, published by Mary Ann Liebert, Inc., 
New Rochelle, NY 
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Step 1: Preparation of collagen solution and dispensing collagen solution into 
molds. Collagen for creating 3D microenvironment is collagen type I, which is extracted 
from rat tail. Collagen dissolves in 1% acetic acid and the concentration is 3.5 mg/mL. 
Neutralized collagen can be filled in each particles’ wells.  
Step 2: Cross-linking of collagen particles. The whole device is placed in incubation at 
37
o
C for 5 to 10 minutes for curing collagen. 
Step 3: Rinsing process. The whole device is merged into 1x PBS or culture media after 
curing.  
Step 4: Air injection and expansion of particles’ wells. Air is pumped into pneumatic 
soft micromold device for expanding particles’ wells. As pressure is increasing, micro-
patterns enlarge and PBS or culture media would diffuse into small gaps between 
collagen microstructures and molds.  
Step 5: Floating and pushing of collagen particles. Collagen particles start floating 
because large amount PBS or culture media is diffused into individual molds. In 
addition, the bottom of PASMO is simultaneously extruded to push collagen particles 
and they are released into PBS or culture media. 
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Figure 7 Mechanism of pneumatic actuated soft micromold and its structure. Right side presents the 
working strategy for pneumatic actuator, which composes soft material on top and stiff material at bottom. 
Top layer would perform obvious deformation. Left side is the schematic diagram for pneumatic actuated 
soft micromold (PASMO) and its structure, particles’ template, air channel and resistance 
 
 
 
 
 
Figure 8 Schematic diagram of collagen microstructure production process via PASMO device. There are 
five steps for this extraction process 1: Dispensing collagen solution into molds; Step 2: Cross-linking of 
collagen microparticles; Step 3: Rinsing process; Step4: Air injection and expansion of micro-mold; Step 
5: Floating and pushing of collagen microparticles 
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2.2 Fabrication process of pneumatic soft micromold device (PASMO)  
The fabrication process of PASMO device is shown in Figure 9(a-d). The master-
mold for the surface template layer is made via the standard photolithographic process 
with SU8 photoresist as described previously.
86-87
 A PDMS solution is spin-coated on 
the master-mold and cured at 65 °C for 2 hours, then, peeled from the master-mold 
(Figure 9a). The master molds for the pneumatic system and barrier layers are made by 
Envision tech 3D printer. Un-cured Ecoflex-30
®
 is poured over a pneumatic system 
mold and cured for 4 hours at room temperature, and peeled from the mold (Figure 9b). 
The width and depth of channel inside the pneumatic system layer are 1.5 mm and 3.0 
mm, respectively. A cleaning cloth with high tensile stress is placed inside the barrier 
layer mold and encapsulated in this layer; then, uncured Ecoflex-30
®
 is dispensed over 
the cloth in the mold. Ecoflex-30
®
 is cured at room temperature for four hours and 
peeled from the mold (Figure 9c). Surface template, pneumatic system and barrier layers 
are subsequently bonded at 65
o
C for two hours with uncured Ecoflex-30
®
 used as glue 
between layers (Figure 9d). The image of PASMO device with a tube attached for 
applying pneumatic pressure is shown in Figure 9e.  
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Figure 9 Schematic diagram of fabrication process for Soft micro mold device. Molding process of (a) 
surface template layer (b) pneumatic system layer (c) barrier layer.  (d) The bonding process of these three 
layers. (e) Photographic image of PASMO device with tygon tubing. (f) Collagen microstructure 
fabrication process. Filling collagen solution into surface templates and curing at 37
o
C. (g) Microscopic 
image of micro scale surface templates of cross prism shape. (h) Collagen microstructure extraction 
process with pneumatic actuation. This is side view as shown the arrow in Figure 9e 
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3. CHARACTERIZATION OF PASMO

 
3.1 Photographic image and operation for soft micromold device 
Figure 10 shows the photographic image of entire pneumatic soft micro mold 
(PASMO) device, which consists syringe pump and PASMO device that are connected 
by tygon tubing. Pneumatic pressure is applied to PASMO device by compressing 
syringe, as a result, the micro-mold is extended and deformed as convex shape. The 
pressure to optimize the deformation of PASMO device and extraction of collagen 
microstructures is set as 1.1, 1.2, 1.7, 2.0 and 2.5 atm. 
 
 
 
Figure 10 Photographic image of pneumatic actuated soft micromold device. Pneumatic actuated soft 
micromold (PASMO) device is consisted with syringe, micromold and connecting Tygon tube   
 
3.2 Characterization for deformation of patterns on PASMO device  
The deformations of PASMO devices are the key to clean extraction of collagen 
micro-structures; therefore, it is important to characterize the deformations of individual 
micro-patterns by pneumatic actuation. Figure 11 shows the microscopic images of 
                                                 

 Reprinted with permission from SOFT ROBOTICS, Year 2017, published by Mary Ann Liebert, Inc., 
New Rochelle, NY 
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cross-shaped micro-patterns on PASMO devices with the pressure application from 1atm 
(no pressure) to 2.5atm, while Figure 11a-f consists of the schematic diagram of 3D 
deformation of micro-pattern. The scaled expansion rate defined as (W0-W1)/W0, (W0: 
the initial width of pattern, W1: the pattern width after injecting air) for the cross shape 
micro patterns in X width at the position 1 to position 5 in Figure 11B are 10%, 35%, 
108%, 78%, and 81%, respectively with 2.5 atm pressure application. The graph of the 
expansion rate of cross-shaped micro-pattern in X width as function of applied pressure 
is shown in Figure 11-a. The highest expansion rate of micro-mold is observed at the 
position 3 at Figure11-f. The Y width is also expanded 16%, 18%, 60%, 31 % and 47% 
at the position 1 to position 5 in Figure 1B, respectively with 2.5 atm pressure 
application. The averaged expansion rate from positions 1-5 in X width is 62.4% that is 
higher than one in Y width (60%) shown in Figure 11B-b. The expansion rate in X and 
Y width is determined by the design of channel network and it can be easily improved 
by the channel network design. In addition to X, Y width, the depth of micro-pattern is 
reduced linearly from 100 µm to 56 µm with pressure increased as shown in Figure 11D. 
This Z directional extrusion from the bottom of micro-pattern increases the successful 
rate of microstructure extraction process. The expansion rate of micro-pattern on the 
surface template layer is linearly proportional to the pressure application. In addition, 
expansion of micro-pattern and extrusion of bottom of micro-pattern improves the 
extraction of collagen microstructures from micro-patterns. 
 
 
 27 
 
3.3 Preparation of collagen microparticles through PASMO device  
The concentration of the rat-tail collagen type I solution is set to 3.5 mg/mL for the 
entire set of experiments. This collagen solution is dispensed into the surface templates 
and gelled under the neutral condition (pH =7.4) at 37
o
C for one hour (Figure 9f). The 
microscopic image of the surface layer with the collagen solution is shown in Figure 9g. 
Pneumatic pressure is applied to the pneumatic channel from a syringe pump, which 
leads to the deformation of PASMO devices and the subsequent release and harvest of 
collagen microstructures in PBS, as shown in Figure 9h. Due to the high tensile stress of 
the cleaning cloth inside the bottom layer, the PASMO device deforms asymmetrically 
with the surface layer expanding the most while the bottom remains intact, which 
promotes the extraction of collagen microstructures from the surface template layer.  
Figure 12 presents the microscopic images of collagen microstructures of cross 
column (Figure 12a), pentagonal prism (Figure 12c), hollow cylinder (Figure 12e), 
triangular prism (Figure 12g), and square pad (Figure 12i) produced via PASMO 
devices. Then, in order to characterize the size reproducibility, the dimensions of the 
structures are compared to those of mold patterns (Figure 12b, d, f, h and j). The results 
show an approximately 96% accuracy for each microstructures ranging from 100 to 
1000 μm, as shown in Figure 12k. On the other hand, the reproducibility of collagen 
microstructures smaller than 100 μm is limited, as the collagen solution is not 
completely dispensed into micro patterns. The thickness of microstructures is set to 100 
µm for all structures and is duplicated with more than 92% accuracy as shown in Figure 
13. Compared to manually pushing gelled collagen particles from the micro-patterns by 
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hand, the extraction forces in PASMO devices are easily controlled and can extract 
fragile collagen structures from molds by applying an incrementally bigger volume of air 
into the pneumatic channel. The successful extraction rates of micro cross-collagen by 
the PASMO device and manual pushing approach are 95% and 15%, respectively, as 
shown in Figure 14. Figure 14 further demonstrates the structural damages observed 
among those collagen microparticles extracted manually by hand. It shows microscopic 
images of collagen micro-cross-columns extracted by soft micro-mold (PASMO, Figure 
14A) device and traditional manual pushing (Figure 14B), respectively. Collagen micro-
cross-column extracted by PASMO device maintains dimensions and shapes. Micro 
cross columns extracted by manual pushing is normally damaged as shown in Figure 
14B. The successful extraction rate for both approaches are shown in Figure 14C. It is 
obvious that PASMO device demonstrate significantly better extraction success data that 
improves reproducibility of collagen microstructure production. 
Figure 12l shows the result of second harmonic generation (SHG) microscopic 
images of collagen micro-cross column to characterize their collagen fiber structures. 
The density of collagen fiber distribution is determined using Image J to be 86.57%, 
which is higher than that of collagen microspheres produced in microfluidic devices 
(62.45%)
88-94
. This matches the density range of collagen fiber in dermis, bone, tendon 
and ligament (72-94%).
95
 In addition, the relatively dense collagen microstructures can 
remain intact when they are injected into an agarose gel without being damaged, unlike 
their less dense collagen microsphere counterparts, as shown in Figure 15.  
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It shows the comparison collagen microstructures made by PASMO device and 
microfluidic emulsion process before and after injection through 19 gauge syringe 
needle. Microscopic images of collagen microparticles made by microfluidic device and 
micro cross-prism made by PASMO devices are shown in Figure 15A and C before the 
injection to agarose gel. Microscopic images of these microstructures after injections are 
shown in Figure 15B and D after injection process through 19 gauge syringe into 
agarose gel. Collagen microspheres are fragmented and merged other after injection 
process even with surfactant during this injection process. (Figure 15B, D) While 
collagen micro-cross column made by PASMO device overcome the pressure drop 
during injection process to agarose gel, the shape and the size of collagen micro-cross-
column are maintained same as the original ones. (Figure 15C, D).  Second harmonic 
generation (SHG) microscopic images of microstructures made by these two approaches 
are shown in Figure 15E and F The collagen fiber density of these two microstructures 
are calculated by Image J and shown in Figure 15G. This demonstrates that collagen 
microstructures made by PASMO devices are suitable for implantable 3D tissue 
engineering applications. 
In addition, collagen microstructures produced by PASMO devices maintain their 
dimensions and shapes, with no observable shrinkage or expansion in size over 50 hours 
(Figure 12m). Thus, PASMO devices are able to precisely control the dimensions and 
shapes of collagen microstructures. These collagen microstructures are stored in the 4 °C 
refrigerator for up to 60 days without any shape changes. 
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Figure 11 Deformation of micro-pattern on PASMO device with pneumatic actuation. (A). Microscopic 
images of micro-patterns with pressure application. (a) 1 atm (no injection of air) (b) 1.1 atm (0.2 mL 
injection) (c) 1.2 atm (0.4 mL air injection) (d) 1.7 atm (0.8 mL air injection) (e) 2.0 atm (1 mL air 
injection) of pressure are applied. Scale bar is 100 µm for all images. (f) Schematic diagram of PASMO 
device (B). The deformation of soft micro-patterns at x, y-width and z-direction based on their location on 
PASMO devices shown in Figure 11f 
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Figure 12 Characterization of collagen microstructures made by PASMO device. Microscopic images of 
microstructures and molds for (a-b) cross column, (c-d) pentagonal column, (e-f) hollow circular cylinder, 
(g-h) triangular column, (i-j), square pad, respectively. The thickness of these microstructures are set to 
100 µm. (k) Duplication accuracy as function of dimensions of micro molds.  (l) Second harmonic 
generation microscopic image of collagen fibers in micro cross column. (Red and white scale bar are 500, 
100 µm, respectively.) (m) Dimensions of collagen micro-cubes as function of times after productions 
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Figure 13 The thickness of collagen microstructure. Side view of (A) Cross Column (B) Hollo Circular 
Pillar (C) Pentagonal Prism (D) Duplication of thickness for collagen microparticles with cross column, 
hollow circular pillar, cube and pentagonal prism 
 
 
 
Figure 14 Collagen microstructures extracted from mold patterns by (A) PASMO device, (B) manual 
pushing. (C) The graph for microstructure extraction success rate between PASMO device and manual 
pushing approaches. The scale bar is 500 μm. 
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Figure 15 The effect of injection of collagen microstructures made by microfluidic emulsion and soft 
micro mold device. Collagen microspheres made by microfluidic device (A)before and (B) after injection. 
Collagen micro cross column made by soft micromold (PASMO) device (C). before and (D) after 
injection. (E)SHG microscope image of (F) collagen microparticles made by microfluidic and of (G) 
micro-cross column made by PASMO device 
  
 34 
 
4. CANCER IN 3D MICROENVIRONMENT

 
4.1 Preparation of collagen microparticle contained MDA-MB-231  
The PASMO device also produces collagen microstructures encapsulating MDA-
MB-231-GFP cells that overexpress Green Fluorescence Protein (GFP) as long as they 
are viable. The cellular concentration for all experiments is set to 10
6
 cell/mL. The 
cellular proliferation and contraction of collagen microstructures are investigated as 
potential collagen modular microenvironment. For cell encapsulation inside collagen 
micro-structures, MDA-MB-231-GFP cells overexpressing Green Fluorescent Protein 
(GFP) are mixed with a 3.5 mg/mL collagen solution as previously described and 
dispensed into surface templates.
96-98
 Collagen microstructures with embedded cells are 
released from the deformed surface template layers of PASMO devices into Dulbecco’s 
Minimal Essential Medium (DMEM) with 10% fetal bovine serum (FBS). Cells inside 
collagen microstructures are cultured in a humidified incubator (5% CO2 and 95% air 
condition) at 37
o
C for more than 14 days. 
Figure 16a shows fluorescent images of MDA-MB-231-GFP cells encapsulated in 
collagen micro-cubes for 0, 4, 8 and 12 days. The fluorescent intensities in the micro-
cube and normalized micro-cube volume as a function of days are also plotted in Figure 
16b. Bright spots on the surface or inside of the collagen structures correspond to MDA-
MB-231-GFP cells. Over time, the fluorescent signal tends to increase in intensity, 
indicating the proliferation of MDA-MB-231-GFP cells in collagen micro-cubes and 
remains for more than 14 days. The volumetric shrinkage of collagen micro-cubes is also 
                                                 

 Reprinted with permission from SOFT ROBOTICS, Year 2017, published by Mary Ann Liebert, Inc., 
New Rochelle, NY 
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significant after the 4
th
 day due to the increase in the number of cells. Figure 16c 
presents the volumetric shrinkage of collagen micro-cubes. Cancer cells generate 
contractile force in order to rearrange the collagen orientation. We encapsulate MDA-
MB-231-GFP cells in collagen micro-cubes with 300, 500, and 1000 um, respectively. 
And the concentration of cells is set to 10
6
 cells/mL. After 7 days, the volume of micro-
cubes would remain 40% of original size. There is no difference of contraction ratio 
among these three different sizes of micro cubes.   
In addition, Figure 16a, c shows the volumetric shrinkage of collagen micro-cubes 
containing cancer cells as a function of days for three sizes of micro-cubes (1000 µm, 
500 µm and 300 µm). There are no significant differences among them because the 
number of cells per unit volume is set to be constant.  Figure 16c show fluorescent 
images of the micro-cross column encapsulating cells on day 0, 3 and 7.  From Day 0 to 
Day 3, they are slightly contracted comparing to the originals; by Day 3, the volumetric 
shrinkage is around 22%. Between 3
rd
 to 7
th
 days, the structure shrinks significantly by 
60%. The micro-cross column is deformed irregularly from the original one, unlike the 
shape-steady micro-cubes, which suggests an existence of an interesting shape-
dependent shrinkage behavior. To extend the application of collagen-based 3D 
microenvironment to clinical test, high throughput is the key requirement. The 1
st
 
generation of PASMO is constructed on the straight channel. However, the most 
deformed area occurred at the center part from the result from either experiment or 
simulation. While, there is less deformation around edge part. On the other hand, 
collagen particles locating at edge part are not easily extracted from microwells. 
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Therefore, we design 2
nd
 generation of PASMO. Figure 17 present the design of 2
nd
 
generation of PASMO. The 2
nd
 generation of PASMO is also composed by three layers, 
which are microparticles template, channel layer, and resistance layer, as top, middle, 
and bottom layer, respectively. The only different design is the shape of channel and the 
shape is designed as circular shape instead of straight channel. We use Ogden model to 
simulate the deformation of PASMO within straight and circular design.  
 
   
 
 
Figure 16 MDA-MB-231-GFP Cell-collagen microparticles. (a) Cell morphology in collagen 
microparticles (b) Fluorescent microscopic images of micro-cubes containing MDA-MB-231-GFP cells at 
day 0, 4, 8, 12.  The graphs for fluorescent intensity and volumetric shrinkage of collagen micro cubes as a 
function of days. Scale bar is 500µm.  (c) The volume shrinkage of collagen micro-cube with 300, 500, 
and 1000μm dimensions as function of days 
 
4.2 Simulation of Pneumatic actuated soft micromold 
The Ogden material model is a hyperelastic material model used to describe the non-
linear stress-strain behavior of complex materials such as rubbers, polymers, and 
biological tissue. The model was developed by Ray W. Ogden in 1972.
99
 The Ogden 
model, like other hyperelastic material models, assumes that the material behavior can 
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be described by means of a strain energy density function, from which the stress–strain 
relationships can be derived. 
𝑈 = ∑
2𝜇𝑖
𝛼𝑖
2 (?̅?1
𝛼𝑖
𝑁
𝑖=1
+ ?̅?2
𝛼𝑖 + ?̅?3
𝛼𝑖 − 3) + ∑
1
𝐷𝑖
(𝐽𝑒𝑙 − 1)2𝑖
𝑁
𝑖=1
 
𝑤ℎ𝑒𝑟𝑒𝜇𝑖, 𝛼𝑖 , 𝑁, 𝑎𝑛𝑑 𝐷𝑖  𝑎𝑟𝑒 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 𝑐𝑜𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
𝜆?̅? = 𝐽
−1/3 𝑓𝑜𝑟 𝑗 = 1,2,3 𝐽 𝑖𝑠 𝑡ℎ𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 
Shear modulus (G) can be determined by 
𝐺 = ∑ 𝜇𝑖 𝑓𝑜𝑟 𝑠𝑖𝑙𝑖𝑐𝑜𝑛𝑒, 𝑁 = 1
𝑁
𝑖=1
 
Poission Ratio can be calculated by Di and G 
𝐷1 =
3
𝐺
(1 − 2𝜈)
(1 + 𝜐)
 
µ1=0.011114056, µ2=1.119657985E-005, µ3=0.01144378401  
α1=2.39364222, α2=8.1236594, α3=-2.16818767 
Figure 17b shows the simulation result, which indicate that all wells would deform 
after increasing inside pressure. Compare to the straight channel, circular design would 
effectively eliminate the edge effect of straight channel. Moreover, the deformed height 
and area is also improved in circular design, especially for expanded area. Figure 18 
demonstrated that the expanded area is changed from 10 mm
2
 to 27 mm
2
 under the 
pressure at 0.04MPa. On the other hand, culture media or buffer solution can be easy to 
fill in expanded microwells in order to float microparticles out. 2
nd
 generation PASMO 
is not only effectively eliminate the edge effect but also improve the production rate for 
making collagen-based 3D microenvironment. 
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Figure 17 The schematic diagram for PASMO (a) Whole image of PASMO (b) PASMO is composed by 
three layers, template, channel, and resist layer (c) The working of PAMS before and after air injection 
 
 
Figure 18 Comparison between straight channel design and circular channel design. The table arranges the 
straight channel and circular channel within 3D view, simulation of channel part and mold part, 
respectively. Compare to the expanded area, the circular design can perform higher expansion. 
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Collagen-based 3D microenvironment is more close to in vivo study because the 
scaffold based cultures has additional interaction between cells and matrix, which lose in 
cellular spheroids. Moreover, the cellular complexity in scaffold-based cultures is much 
higher than cellular spheroids. Many researches also mentioned drug candidates lose 
efficiency in a 3D microenvironment compare to 2D and cellular spheroids. (Figure 
19)
100-102
 Herein, we treated paclitaxel to MDA-MB-231-GFP in collagen-based 3D 
microenvironment and monitor the drug effect over 7 days.  
 
 
 
Figure 19 Rethinking drug screening processes. Tissue engineering provides 3D cultures that recreate the 
complex cellular microenvironment more precisely than traditional 2D cultures, due to the incorporation 
of multiple physical, mechanical and chemical cues that arise from ECM-cell and cell-cell interactions. At 
the opposite end of the experimental continuum, animals do not capture important facets of human 
behavior and they are not feasible for HTS applications. Therefore, 3D cultures can bridge the gap 
between 2D cultures and animal models. (Redrawn from Ref. 100) 
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4.3 Collagen-based 3D microenvironment for sensing of Paclitaxel  
Figure 20 presents the mechanism of Paclitaxel for defeating cancer cells. Paclitaxel 
is a well-known anti-cancer drug and its mechanism is to block the chromosome 
segregation through damage the mitotic spindle. This inhibited function is general to 
contribute its suppression of DNA duplication so that the mitosis would be interrupted. 
As a result, cancer cells would trigger the apoptosis process and lose their biological 
function.
103-107
 On the other hand, the contractile force of cancer cells would be 
eliminated after treating paclitaxel. Therefore, we can observe the shrinkage of collagen-
based 3D microenvironment under different concentrations of Paclitaxel.  
 
 
Figure 20 The mechanism of Paclitaxel for treating and inhibiting the survival of cancer cells. Paclitaxel 
inhibit the activity of mitotic spindle in order to destroy the mitosis. Abnormal dipoles cells would 
generate and trigger apoptosis process. (Redrawn from Ref. 103) 
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Collagen microparticles encapsulating cancer cells are exposed to 1, 0.1, and 0.01 
µM concentrations of paclitaxel solutions. Cell proliferation and the size of collagen 
microstructures are investigated over 7 days. Figure 21d, e and f show fluorescence 
images of collagen micro-cubes exposed to paclitaxel with concentrations of 1, 0.1, and 
0.01 µM on days 0, 3 and 7. Paclitaxel is a commonly used anti-cancer drug, and it 
stabilizes cellular microtubules that terminate the contraction of MDA-MB-231-GFP in 
collagen.
108
 The volumes of collagen micro-cubes reduce to 40, 50, and 67% of original 
size with paclitaxel concentrations of 1, 0.1, and 0.01 µM, respectively, on the 7
th
 day. 
Compared to micro-cubes without paclitaxel, micro-cubes exposed to 0.1 and 1 µM have 
far less overall volumetric shrinkage. On the other hand, micro-cubes with 0.01 µM 
paclitaxel have almost the same volumetric shrinkage rate as micro-cubes without 
paclitaxel due to less stabilization of microtubules among cancer cell. The volumetric 
shrinkage ratio for collagen micro-cubes without cells, collagen micro-cubes and cross-
columns with cells, micro-cubes with cells exposed to paclitaxel as a function of days 
are all plotted in Figure 21g. Colby et al. also observe that paclitaxel can inhibit the 
cancer growth in 3D microenvironment.
109
 Compared to control (without treating 
paclitaxel), the size of microenvironment is larger than control group. It indicates that 
biological function can observe the inhibition of cancer cell growth and can monitor the 
surrounding stimuli in 3D microenvironment. 
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Figure 21 MDA-MB-231-GFP Cell-collagen microparticles (a) Fluorescent microscopic images of micro-
cubes containing MDA-MB-231-GFP cells at day 0, 4, 8, 12.  The graphs for fluorescent intensity and 
volumetric shrinkage of collagen micro cubes as a function of days. Scale bar is 500µm.  Fluorescence 
microscopic images of (b) micro-cubes, (c)micro-cross column, micro cubes containing MDA-MB-231-
GFP cells exposed to (d) 0.01, (e) 0.1, and (f) 1 µM paclitaxel at day 0, 3 and 7.  Scale bar is 500 µm. 
 
Moreover, collagen-based 3D micropartilces creating from PASMO can be applied 
in cancer xenograft. Cancer xenograft plays a crucial role for cancer treatment because 
of discovering drugs and finding suitable treatment for patients.
110
 The widely method 
for setting cancer model is to mix scaffold with cancer cell line and then inject into nude 
mice in vein. The disadvantage of injection of vein is that cancer cells cannot be housed 
at specific location. If the number of cells at specific location is not high enough, the 
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tumor cannot be formed easily. PASMO overcomes this problem because it can generate 
microenvironment for cancer cells, especially extremely soft material, like collagen or 
Matrigel
TM
. 
Figure 22 present the procedure for cancer xenograft and Matrigel
TM
 is the target 
material for cancer xenograft. Matrigel
TM
 is derived from reconstituted basement 
membrane form the Engelbret-Holm-Swarm tumor and Bissell group demonstrated that 
Matrigel
TM
 has important mechanical and chemical properties to illuminate the 
morphological and functional tumor behavior.
111
 However, cancer xenograft would have 
large variety for tumor size because traditional method is to mix suspended cells with 
Matrigel
TM
 and then inject into nude mice in vein. Therefore, cancer cells would spread 
everywhere in nude mice. Once the level of communication between cells is not well, 
the tumor would not be formed in nude mice. To overcome this large variety and low 
successful rate, we can make Matrigel
TM
 3D microenvironment to confine and localize 
cancer cells at specific location. However, there is no tool to make Matrigel
TM
 3D 
microenvironment for xenograft because Matrigel
TM
 is an extremely soft material. 
Therefore, we can use PASMO to overcome this disadvantage.  
We mixed pancreatic tumor cells (AsPC1 Luc cells) with Matrigel
TM
 and filled out 
the each wells for making microenvironment. Until solidification of Matrigel
TM
, we 
deform template through injecting air into channel. The Matrigel
TM
 particles will be 
released from template because extended wells create some space between particles and 
mold. Therefore, particles in templates can be easily to push and wash out. Particles 
from PBS are implanted into nude mice. After 7 days, we can observe tumor is formed 
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in each nude mice. (Figure 23) Compare with control (classical orthotopic model), the 
successful rate is improved. To consider the volume of tumor, the average of tumor 
volume is at 12-14mm
3
, while the tumor volume in the classical method is from 3.5 to 
14.5mm
3
. PASMO method can be effectively minimized the variety of cancer xenograft 
model. 
 
 
Figure 22 The preparation of xenograft model for AsPC1 Luc cells. AsPC1 Luc cells mixed with 
Materigel
TM
 and then injected into particles’ template of PASMO device for solidification under 37oC. 
Take off Matrigel
TM
 particles contained AsPC1 Luc cells and implant into nude mice for observing the 
formation of tumor. The optical image at right hand side is Matrigel
TM
 contained AsPC1 is filled in 
pneumatically actuated soft micromold device.  
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Figure 23 Classical Orthotopic and Matrigel
TM
 particle methods for xenograft model experiment. (a) The 
bioluminescence images of cancer tissue prepared by the classical orthotopic method and Matrigel 
particles. Only one nude mice prepared by the classical orthotopic method has response at day zero. All 
three mice prepare by Matrigel particles have response at day zero. After 7 days, the bioluminescence 
signal of cancer tissue prepared by classical orthotopic method decreases due to cancer cells spreaded 
entire body. On the other hand, three mice prepare by Matrigel particles have strong cancer tissue signals. 
Classical orthotopic method is not able to hold the cells maintaining in the defined volume after injection. 
Therefore, it might spread closer to skin surface area which caused the signal stronger. However, it might 
also move to deeper tissue area or diffuse in circulation which caused less signal. PASMO-Matrigel
TM
 
already pre-defined the cells within the gel so the signals can be more homogenous. (b) Ultrasonic 
scanning image of tumor tissue prepared by the classical orthotopic method and Matrigel particles at day 
14. Photo images of tumor tissue removed from mice prepared by the classical orthotopic method and 
Matrigel particles are also shown.  (c) The average tumor volumes prepared by the classical orthotopic 
method and Matrigel particles. Matrigel
TM
 based tumor tissue particles can effectively reduce the 
fluctuation of tumor volume. 
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5. ARTIFICIAL ISLETS FOR TYPE I DIABETES TREATMENT  
5.1 History of the treatment for type I diabetes  
Early stage diabetes patient require strict diet and exercise regimes to control the 
glucose concentration in blood; if the disease is progressed, patients need to inject 
insulin. As the stage of diabetes progresses further, diabetic complications, such as heart 
and blood vessel disease, nerve and eye damages, are often reported. To delay such 
complications, the glucose concentration in blood should be controlled precisely by 
multiple insulin injections a day, which has led to varied and often unsatisfying results.  
For a precise control of the glucose level in blood, numerous insulin delivery methods 
have been investigated over the past 20 years. The more established delivery methods 
range from the insulin inhaler,
112
 skin patch delivery,
113
 insulin pills,
114-115
 to the most 
drastic method of pancreas transplantation.
116
 Despite varied success, the 
aforementioned methods exhibit problems with delivery efficiency,
112-115
 as well as 
potential discomforts. For instance, even the most clinically accepted insulin inhaler 
(Afreeza marketed by Sanofi) is known to cause dizziness, lung problems and irritation 
in the back of the mouth.
112
 The latest technology in insulin delivery focuses on the 
encapsulation of beta cells in different media, such as nano-sized pores,
117 
polysaccharide (alginate),
118
 and polyethylene glycol (PEG).
119
 Most study were using 
PEGDA to generate microenvironment through imprint lithography,
120-123
 continuous 
flow lithography (CFL),
124
 and stop flow lithography (SFL)
125
 to pattern microparticles 
and encapsulate beta cells or islet. Cells are mixed with Polyethylene (glycol) Diacrylate 
(PEGDA) and are dispended to the pattern. However, PEGDA does not have biological 
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sequence to provide adhesion site for beta cells. Therefore, PEGDA need to modify short 
peptide sequence, like RGD, IKLLI, IKVAV (laminin sequence) and DGEA (collagen 
type I sequence) to improve cell viability and reduce apoptosis.
126
 Also, the insulin 
secretion can be also improved by conjugating EphA5-Fc receptor and ephrinA5-Fc 
ligand.
127
 Although the biological function is adjustable, these approaches are just to 
realize the interaction between peptide sequence and beta cells rather than to mimic the 
microenvironment for islets and beta cells. Furthermore, the solidification of PEGDA 
would damage cells because UV-photoinduced cross-linking. Photoinduced cross-linked 
polymer is polymerized by radical reaction so that UV light would damage cells and 
then induce cell cytosis and apoptosis during the preparation. While in the preclinical 
stage of development, nano-pore immune-isolation devices are highly costly to fabricate. 
On the other hand, PEG reports inflammation and potential immune complications,
128-129
 
particularly due to the fact that alginate does not originate from the human body. 
Collagen is one of the most important extracellular matrix in creating the cellular 
microenvironment without immnumoresponse, which is similar to the case of islet or 
beta cells.
130
 To culture beta cells or islet in collagen matrix would suppress the dell 
death and maintain the biological function. Nagata et al. monitored mRNA levels 
(insulin, glucagon, somatostatin) and secretion levels (HCF, IL-1α and 1β) expressed in 
collagen matrix to recognize as major insulin secretion and cytotoxic factors for 
pancreatic beta cells. mRNA levels maintained the same level, while secretion levels 
does not change after culturing in collagen matrix. It indicates that encapsulated beta 
cells in collagen microenvironment would not interfere biological function.
131-133
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Currently, several methods to produce collagen microparticles have been reported. 
For instance, mono-dispersed microfluidic approach is used to create collagen 
microspheres.
134-140
 While the high throughput production is the main advantage, this 
approach has not been successful in biomedical application because oil phase would 
inhibit the cellular function in collagen-based microenvironment. Oil-to-water emulsion 
is an unsolved system to make microsphere. Therefore, oil phase would attach and 
absorb on the surface of microspheres. Consequently, cellular function would be 
inhibited. Furthermore, the abnormal cellular function would occur. In addition, the 
extraction process of collagen microparticles from oil phase would cause contamination 
and damage of microparticles. Collapsed and merged micropartilces would also undergo 
during extraction process. On the other hand, the non-uniform collagen microparticles 
would be happened after extraction process.  
Replica molding,
141
 Particle Replication In Non-wetting Templates (PRINT
TM
),
142-
143 
and bottomless molding technique,
144
 are used to produce stable and chemically or 
physically cross-linked materials, such as alginate or collagen. Gelated collagen 
microparticles are extracted from the templates manually pushing molds. These 
approaches are the only technique to produce collagen particles, however it has very low 
throughput and the extraction of particles without damage is still challenging due to the 
inherent softness of collagen. Squeezing the micro-mold is the most traditional method 
of extraction but the inhomogeneous extraction force easily damages soft collagen 
microparticles. In conclusion, no technique is presently available to synthesize a large 
number of collagen microparticles, economically, reliably and reproducibly. 
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In this study, we developed pneumatic actuator to gently extract collagen 
microparticles. This pneumatic actuator is composed by three sections shown in Figure 
24a. These three sections are particles’ template, air channel, and resistance layer. The 
working strategy of cPASMO device can be classified as four steps to release collagen 
microparticles. First of all, the collagen solution is filled into each wells located on 
particles’ template and incubate it at 37oC for 30 min for solidification. Second, air is 
injected into air channel to increase the inner pressure for deformation. According to the 
asymmetric mechanical properties of cPASMO device, the deformation of particles’ 
template is more obvious than resistance layer. Therefore, the gap would generate 
between mold and collagen microparticles. Thirdly, buffer or culture media can diffuse 
into the gaps to float and push collagen microparticles out without damage. Finally, 
collagen microparticles can be collected from buffer or culture media for monitoring the 
cellular response. Herein, we use cPASMO device to produce artificial islet through 
encapsulating beta cells and monitor the concentration of insulin secreted from 
encapsulated beta cells.  
5.2 Fabrication of circular pneumatic actuated soft micromold  
The circular Pneumatic Actuated Soft Microfmold (cPASMO), shown in Figure 24a 
is constructed by three layers. Top layer is the particles’ template, which is used to 
generate collagen microparticles and middle layer is air channel for creating the 
pneumatic actuation. This actuation can deform particles’ template in order to generate 
gaps for releasing collagen microparticles. Moreover, pneumatic actuation is controllable 
through varying the injected volume and injected rate of air so that collagen 
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microparticles can be extracted gently. The bottom layer, third layer, performs stronger 
mechanical property and constructs a resistance for deforming from bottom side. On the 
other hand, the bottom resistance distributes and transports pneumatic force to particles’ 
template for deformation. Figure 24b to 24d presents the process to prepare particles’ 
template, air channel and resistance layer, respectively.  Particles’ template and air 
channel layer of cPASMO device are fabricated by Ecoflex-30
®
, while the resistance 
layer is composed by Ecoflex-30
®
-cloth composite, which has stronger mechanical 
properties. Each layer is duplicated from 3D-printed mold, which is printed from 
EnvisionTec. The uncured Ecoflex-30
®
 is poured in 3D-printed mold for making 
particles’ template, air channel and resistance layer, respectively. Then, the bonding 
between these three layers is operated by Ecoflex-30
®
 and the curing time is 4 hours at 
room temperature.  
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Figure 24 Schematic diagram of circular pneumatic actuated soft micromolds (cPASMO) device (a) 3D 
and top view of circular PASMO device, which is composed by three layers, template layer, channel part 
and resist layer. Molds is printed through 3D printer. (b-d) The master mold of particles’ template, air 
channel and resistance are prepared from 3D printer, respectively. Pour uncured Ecoflex-30
®
 into each 
mold and cure it for 4 hours at room temperature. After solidification, the parts of cPASMO can be peeled 
from mold. Uncure Ecoflex-30
®
 is used as glue to bond these layers for 4 hours.  
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5.3 Preparation of artificial islet for beta-cell encapsulation  
Collagen, alginate, and polyethylene glycol diacrylate (PEGDA) are the target 
matrixes for encapsulating beta cells and producing artificial islet. Collagen 
microparticles are fabricated from collagen type I solution extracted from rat tail and the 
final concentration for cell encapsulation is 3.5mg/mL;
145
 Alginate microparticles are 
constructed by 1% sodium alginate extracted from brown algae and the cross-linking of 
alginate is triggered by 1M calcium chloride. The cross-linking of alginate is 30 
seconds;
124
 PEGDA microparticles are formed by polyethylene glycol diacrylate and its 
average molecular weight is 575Da.
146 
 The mechanism of cross-linking of PEGDA is 
photo-polymerization. Thus, 3% of photoinitiator (2,2-Dimethoxy-2-
phenylacetophenone) is prepared for the cross-linking of PEGDA microparticles. The 
duration of cross-linking of PEGDA is 30 seconds. 
For cell encapsulation inside collagen, alginate and PEGDA microparticles, beta 
cells are mix with 3.5 mg/mL collagen solution and PEGDA solution, respectively. 
Then, these mixtures are dispensed into particles’ template of cPASMO device and 
trigger cross-linking for each material under proper conditions. Solidified microparticles 
are released from the deformed particles’ template of cPASMO device into RPMI-1640 
culture media. There microparticles encapsulated beta cells are cultured in a humidified 
incubator (5% CO2 and 95% air condition) at 37
o
C for more than 14 days and monitor 
the insulin secretion. The concentration of beta cells for all experiments is set to 2×10
7
 
cell/mL. The size for microparticles is 500 µm and 1000 µm in diameter and the 
thickness is 300µm. On the other hand, the average of cell number of 500 µm and 1000 
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µm microparticles are 1180 and 4710, respectively. The cPASMO device is autoclaved 
at 131
o
C for sterilizing. 
Figure 25a presents the schematic diagram of top view of cPASMO. The solid line is 
the boundary of cPASMO device and the dash line is the pattern of air channel, which is 
designed as circular shape. The circular design of air channel expands the particles’ 
template radially when pressurized. This radial expansion not only can create the gap 
between mold and collagen micro-disk but also can reduce the depth of particles’ mold 
to extract collagen particles.  
The dimension and the position of the air channel crucially determine how the 
cPASMO device deforms after increasing the inner pressure. The parameters W, Di, and 
Do stand for the width of air channel, inner diameter and outer diameter, respectively and 
we used W-Di-Do to describe the dimension of cPASMO device. For example, 0.3-1.7-
2.5 indicates that the width of channel, location of air channel, and diameter of cPASMO 
are 0.3, 1.7, and 2.5cm, respectively. Figure 25b presents the relationship between the 
percentage of expanded area and inner pressure. The expanded area increases as a 
function of inner pressure. The larger the inner pressure we generate, the wider the 
expanded area of the cPASMO device are. As a result, the saturated expanded area is 5 
times wider than original size. To simply the name of cPASMO with different designs, 
0.3-1.7-2.5 is called cPASMO_1.7. 
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Figure 25 Circular PASMO deformation at different injected volume of air (a) schematic diagram for 
cPASMO device from top view (b) the expanded area of particles layer of cPASMO. 
 
Herein, we produce four types of cPASMO devices with different positions of air 
channel, which locates at 1.0 (cPASMO_1.0), 1.4 (cPASMO_1.4), 1.7 (cPASMO_1.7), 
and 2.0cm (cPASMO_2.0), respectively, using FE. Figure 26 presents the deformed 
configurations for these four cPASMO devices from the simulation. This table arranges 
side view and top view of deformed cPASMO. The most important characterization is 
that the morphology of expansion of particles’ template is highly related with the 
position of air channel. As in the previous mechanism of releasing particles, generating a 
wider gap between the mold and collagen particles can help releasing of collagen 
microparticles. Moreover, releasing percentage of collagen microparticles is another 
important aspect for producing collagen particles through cPAMSO in order to increase 
the efficiency. Therefore, the optimized cPASMO needs to perform wider generated gap 
and higher releasing rate of collagen microparticles after pneumatic deformation. 
The generated gap is determined by expanded area of each particles’ wells. Figure 3 
presents the expanded area after pneumatic deformation. According to the different 
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expanded level of deformation at different area, particles’ wells are classified as seven 
areas, which indicate area 1 to area 7 from the outer to inner regions shown in Figure 
27a. Figure 27b to 27e presents the distribution of expanded areas from area 1 to area 7 
in cPASMO_1.0 to cPASMO_2.0. The maximum expanded area is located at channel’s 
position because of larger deformation generated from the center of air channel. For 
example, cPASMO_1.0 performs a maximum deformation at area 7, which indicates the 
position of channel. The further location from the air channel decreases the deformation 
level of particles’ well because the pneumatic force cannot propagate through the whole 
cPASMO device. It demonstrates that the outer region, area 1 to area 3 cannot properly 
generate a gap between mold and collagen microparticles. cPASMO_2.0 is designed as 
improving the amount of expanded wells and the design of cPASMO_1.4 is to locate the 
air channel in the middle region, which is close to area 6. This location contributes wider 
distribution of expanded wells and the range of expanded area is 1.1, 2.8, 7.2, 11.1, 10.9, 
9.5, and 3.9 mm
2
 from area 1 to area 7, respectively. Figure 3c shows the distribution of 
expanded area of each particles’ well on cPASMO_1.4. However, the maximum 
deformed particles’ wells is not located at the air channel position. The position of air 
channel for cPASMO_1.0 is located at central region so that the lateral resistance is 
higher than the vertical resistance due to the thickness of Ecoflex-30
®
. The lateral 
thickness is 1.5 cm, while the vertical thickness is 2.0mm. Therefore, the pneumatic 
force contributes to the vertical deformation more than the lateral deformation in 
cPASMO_1.0 design. Once the lateral resistance decreases with decreasing the lateral 
thickness, like cPASMO_1.4, the pneumatic force would contribute to both lateral and 
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vertical deformations. This deformation arrangement helps improving the expansion at 
wider region. Figure 27d shows the distribution of deformed particles’ wells for 
cPASMO_1.7. cPASMO_1.7 shifts the location of air channel to 1.7cm and the 
thickness reduces from 5.5cm (cPASMO_1.4) to 4cm (cPASMO_1.7). The expanded 
areas are 1.8, 6.0, 11.9, 10.3, 10.5, 7.2, and 2.5mm
2
 from area 1 to area 7, respectively 
and the maximum expanded area also follows the position of air channel to shift to area 
3. The deformation of particles’ well and expanded area of each region on cPASMO_1.7 
is similar as cPASMO_1.4 so that cPASMO_1.7 can also contribute radial deformation. 
However, if the position of air channel moves further to 2.0cm called cPASMO_2.0, the 
lateral deformation would more obvious than the vertical deformation because of low 
lateral resistance. The lateral thickness reduces from 5.5mm (cPASMO_1.4) to 2.5mm 
and this position is close to the vertical thickness, 2.0mm, so that the lateral resistance is 
approximately equal to the vertical resistance. The distribution of expanded area shifts to 
outer region, area 3 and the expanded areas for each area are 1.1, 3.0, 5.0, 3.7, 4.3, 1.7, 
and 0.8 mm
2
 from area 1 to area 7, respectively. The pneumatic force generated from air 
channel for cPASMO_2.0 cannot propagate and contribute to central region (area 6 and 
area 7) so that the expanded area of particles’ wells cannot properly produce gaps 
between the collagen microparticles and mold. Figure 28 presents the quantified results 
for serial cPASMO designs, cPASMO_1.0 cPASMO_1.4, cPASMO_1.7, and 
cPASMO_2.0. The amount of deformed particles’ wells and the releasing rate of 
collagen microparticles are important characterization of cPASMO device. We define 
the amount of deformed particles’ wells as follows: 
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𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑒𝑓𝑜𝑟𝑚𝑒𝑑 𝑤𝑒𝑙𝑙𝑠 (%) =
# 𝑜𝑓 𝑑𝑒𝑓𝑜𝑟𝑚𝑒𝑑 𝑤𝑒𝑙𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑙𝑙𝑠
   (1) 
 
Figure 28a summarizes the amount of maximum deformations in wells based on the 
location of air channel. The expanded particles’ wells are located at areas 5 to 7 but the 
particles’ wells posited at area 1 to 4 experience relatively small deformations. The 
amount of areas that can undergo significant deformations in wells for cPASMO_1.0 is 
around 70.4%. Even through cPASMO_1.4, cPASMO_1.7, and cPASMO_2.0 can 
undergo significant deformations, the amount of deformed areas for cPASMO_2.0 is 
around 64.2% due to an undeformed region at the center of the device. From the contour 
plot of cPASMO device in Figure 27, cPASMO_2.0 shows relatively small deformations 
at the center of the device after actuation, indicated by blue region. On the other hand, 
cPASMO_1.4 and cPASMO_1.7 can trigger over 95% of particles’ wells’ deformation. 
Moreover, the average expanded area of cPASMO_1.4 and cPASMO_1.7 can approach 
6.64 and 6.44mm
2, respectively. Compared to the maximum expanded area of particles’ 
wells, cPASMO_1.4 and cPASMO_1.7 can create 11.9 and 11.1mm
2
. Figure 28b 
demonstrates the comparison of expanded areas between these four cPASMO devices. 
Creating larger gap and generating larger mold expansion can enhance the releasing rate 
of collagen micro-disks without damaging the particles. Figure 28c illustrates the 
releasing rate of collagen micro-disks in these four cPASMO devices. The releasing rate 
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of collagen micro-disks is calculated by the ratio of number of released particles and 
total wells. The formula is shown as below: 
 
𝑅𝑒𝑙𝑒𝑎𝑠𝑖𝑛𝑔 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑚𝑖𝑐𝑟𝑜𝑑𝑖𝑠𝑘 (%) =
# 𝑜𝑓 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑙𝑙𝑠
  (2) 
 
The design of cPASMO_1.0 and cPAMSO_2.0 are evident that the releasing rates 
are 54.1% and 50.5%, respectively, while cPASMO_1.4 and cPASMO_1.7 show the 
releasing rates of 95.5% and 90.2% respectively. The results of releasing rate match the 
deformation of cPASMO device. Higher level of expansion and larger amount of 
deformed particles’ wells of cPASMO lead to higher release of undamaged collagen 
micro-disks cPASMO. The optimized designs of cPASMO device are cPASMO_1.4 and 
cPASMO_1.7, whose location of the air channel is in the middle of cPASMO device. 
This design can generate proper magnitude of mold expansion and larger amount of 
deformed particles’ wells. 
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Figure 26 Deformation and actuation of cPASMO device for different dimensions. cPASMO is classified as four group based on the position of air 
channel, cPASMO_1.0, cPAMSO_1.4, cPASMO_1.7, and cPASMO_2.0, respectively and the unit of number is centimeter. In this figure, we present 
the simulated and optical image for different designs after actuation. And the pictures are from top and side views for presenting the deformation for 
each dimensions. The diameter of cPASMO device is 2.5cm. (Scale bar: 2cm) 
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Figure 27 Expanded area of cPASMO device from seven areas. (a) Schematic diagram of micro-disks’ 
mold of cPASMO device and we distinguished as seven areas, area 1 to area 7 from outer to inner, 
respectively. (b) cPASMO_1.0 presents the expanded area varied from area 1 to area 7. The position of air 
channel is located at area 7. (c) cPASMO_1.4 presents the expanded area varied from area 1 to area 7. The 
position of air channel is located at area 6. (d) cPASMO_1.7 presents the expanded area varied from area 1 
to area 7. The position of air channel is located at area 4. (e) cPASMO_2.0 presents the expanded area 
varied from area 1 to area 7. The position of air channel is located at area 3. 
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Figure 28 Comparison and optimization of cPASMO within different dimensions. (a) Amount of deformed 
wells, which is defined as the ratio between the number of expanded wells and total wells. The highest 
percentage of expanded wells is cPASMO_1.4 and cPAMSO_1.7 (b) Comparison of expanded area 
between different dimensions and their expanded areas are proportional to the inner pressure. 
cPASMO_1.4 and cPAMSO_1.7 performed highest expanded area. (c) Comparison of releasing rate of 
collagen micro-disk of cPASMO device and the highest releasing rate is cPASMO_1.4 and cPASMO_1.7. 
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Figure 29 shows the glucose response for collagen based artificial islets under four-
step cycle. The inserted wells are placed on each well of 24 well plate for holding 
suspended artificial islets and this inserted wells have porous to allow the diffusion of 
glucose and secreted insulin. As a result, the secreted insulin level can be monitored 
from collected culture media outside inserted wells. The first step is the control group, 
which includes culture media contained 25mM glucose only and the concentration of 
secreted insulin is 0.251ng/mL. Secondly, 3~4 artificial islets are placed into inserted 
wells and the culture media includes 25mM glucose. After 24 hours culturing, the 
concentration of secreted insulin can approach 2.382ng/mL. Later, the culture media is 
replaced to the culture media lacking of glucose for monitoring the concentration of 
secreted insulin from artificial islet after 45 min incubation. As a result, the 
concentration of secreted insulin decreases to the background value. Finally, the glucose 
is added in culture media again and the concentration of glucose is 25mM. After 45 min 
incubation, the secreted insulin level rises and achieves detectable range. This result 
demonstrates that these articles islets not only can survive in collagen micro-disk but 
also can maintain their biological function, like sensing glucose from surrounding and 
secreting insulin after glucose stimulation. 
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Figure 29 Glucose response of encapsulated beta-cells in collagen disk for secreting insulin. (a) procedure 
of encapsulating beta cells in collagen disk. (b) Microscopic image of collagen disk encapsulated beta cells 
and the cell concentration is 3140 cells per collagen disk (c) Insulin response under four continuous steps. 
First step is that culture media contains glucose only. Second step is to add the collagen disks containing 
beta cells into glucose-culture media. The third step is to replace the culture media, which does not contain 
glucose. The fourth step is for changing back the culture media contained glucose 
 
Figure 30a demonstrates the material effect for encapsulating beta cells. We 
encapsulate beta cells in PEGDA and collagen. The insulin secretion level for PEGDA is 
much less than the one from the collagen-based micro-disks and suspended beta cells. 
This indicates that the cellular function of beta cells already missed after encapsulation 
in PEGDA. On the other hand, the encapsulated beta cells can maintain their cellular 
function, which is related with the interaction between matrix and cells.
125-126,149
 For 
example, RGD functionalized PEGDA can effectively revive encapsulated beta cells for 
sensing glucose and releasing insulin. Moreover, encapsulated beta cells in collagen 
micro-disk perform higher insulin secretion level than suspended beta cells. It proves 
that the insulin secretion depends on the distance between cells for signal transduction. 
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Collagen micro-disk provides an approach to forming cluster for beta cells. Figure S1 
presents the glucose response under four-step cycle test for collagen-based micro-disk. 
This result also demonstrates that the artificial islet can respond to glucose from 
surrounding. Additionally, the secretion of insulin for artificial islets increases as a 
function of glucose concentration. Figure 5b presents that artificial islets are in culture 
media with different concentrations of glucose (2mM, 15mM, and 30mM). Higher 
insulin concentration leads to higher glucose concentration. Moreover, in each 
concentration, artificial islets can secret insulin 3~6 times higher than the suspended one. 
The reason is that the secretion of insulin is determined by the signal communication 
between each beta cell. If the distance between each beta cell is short enough, the 
triggered signal will be transported to more cells. Moreover, we consider different 
dimensions of artificial islets, which is 500µm and 1000µm, respectively. A smaller 
artificial islet can secrete higher insulin even when the number of cells is half of the one 
in the larger artificial islets. One reason for higher insulin secretion from smaller islet is 
due to the diffusion behavior. Smaller collagen microparitcles have less diffusion 
resistance than the larger ones so that smaller microparticles would be easy to sense and 
respond to the change from surroundings. Another reason is that the distance between 
beta cells. The signal transduction between beta cells is proportional to the insulin 
secretion. A closer distance in the micro-disk beta cells produces higher insulin beta 
cells secretion. As a result, smaller artificial islet would secrete higher concentration of 
insulin than the larger one. cPASMO offers a promising approach to fabricate collagen-
based micro-disk as an artificial islet. 
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Figure 30 The performance for secreting insulin at different concentrations of glucose (a) comparison of 
secreting insulin between suspended cells and encapsulated cells in collagen disks and PEGDA disks. The 
glucose concentration in culture media is 15mM and 30mM, respectively. (b) comparison of secreting 
insulin in different size of collagen disks. We produce collagen disks within 0.5mm and 1mm in diameter 
and suspended them in culture media within different concentrations of glucose, 2mM, 15mM, and 30mM.  
 
5.4  Artificial islet implantation  
Type I diabetes mellitus is a group of metabolic diseases in which the insulin 
secretion is abnormal due to losing function of pancreatic islet, especially beta cells.
150
 
The most reliable clinical therapy is islet transplantation, which is called “Edmonton 
protocol”.151 The major issue to impede this surgery is the immunoresponse. The 
isolated islet would induce the immunoresponse because of transplantation immunity.
152
 
Therefore, permanent immunosuppresant would introduce to provide immnuo-tolerance 
after transplantation. For example, tacrolimus and silolimus are the well-known 
immunosuppressants for islet transplantation, however, they impair the islet viability and 
graft function.
153-154
 beta cells encapsulated in collagen microenvironment can reduce the 
immune-response because collagen microenvironment can be used as barrier to avoid 
triggering immune reaction and prevent the adhesion of immune cells.
155-156
 The second 
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issue for islet transplantation is the surgery method. Based on the position, islet 
transplantation would be classified as intravascular and extravascular types. An 
intravascular is directly transplant beta-cell microenvironment into the host artery and 
vein.
157
 The beta-cell microenvironment would attach onto wall of blood vessel. Once 
blood flows through this microenvironment, the oxygen and nutrient would be delivered 
and the water would be taken away. However, the severe problem for intravascular 
transplantation is that the blood clots would be generated in blood vessel. The ideal 
transplantation site for encapsulated beta cells is extravascular, especially intrahepatic 
transplantation. However, intrahepatic transplantation would induce instant blood-
mediated inflammatory reaction (IBMIR, a rapid process for forming thrombus.
158
 To 
improve and reduce IMBIR after transplanting artificial islets, muscle and subcutaneous 
tissue can be considered as the best positions.  
Figure 31a is the process to prepare the sample for islet transplantation. We prepare 
300 collagen-based microparticles contained beta cells, and then transferred them into 
big mold in which the size is 3mm × 3mm × 2mm (height). Collagen precursor is added 
into millimold in order to aggregate 300 collagen microparticles as the clusters. We 
continue with a subcutaneous injection to transplant this cluster into mice. Figure 31b 
shows the testing on mice to check the angiogenesis. The white area is the cluster of 
collagen microparticles and we found the blood vessels (red line) are formed around the 
cluster of collagen microparticles. Moreover, by homogenizing the cluster, the insulin 
secretion can be monitored. We also implant artificial islet clusters at two locations. 
After three weeks, the blood vessels can form around these two clusters and there are 
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blood vessels formed between them, as shown in Figure 32. On the other hand, the 
forming of blood vessel can be used to regulate blood glucose level and the connection 
between tow clusters can improve the efficiency for regulating sugar level in blood. The 
concentration of insulin from this tissue is 163.6pmol/L, which is close to normal 
condition. Artificial islets can potentially compensate the insufficient insulin for type I 
diabetes patients. 
 
 
Figure 31 The process for artificial islet implantation-one location after one week (a) Collagen 
microparticles contained beta cells formed through cPASMO device and 300 microparticles are placed 
into larger PASMO wells. Another collagen solution is poured into wells for clustering these 300 
microparticles. Finally, this cluster is implant into mice under skin and sacrifice mice after one week. (b) 
Blood vessel is formed around the implanted artificial islet and the concentration of secreted insulin is 
approach the normal level. 
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Figure 32 The process for artificial islet implantation-two locations after three weeks. Collagen 
microparticles contained beta cells formed through cPASMO device and 100 microparticles are placed 
into larger PASMO wells. Another collagen solution is poured into wells for clustering these 100 
microparticles. Finally, this cluster is implant into mice under skin and sacrifice mice after one week. 
After 3 weeks and sacrificing mice, blood vessel is also formed around the implanted artificial islet and 
there is connection between two implanted beta cells clusters. 
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6. SUMMARY 
In this dissertation, two different designs of pneumatic actuated soft micromold 
(PASMO) are used to generate collagen microstructure within different dimensions and 
different morphologies. An overview of design of PASMO device is given as an 
introduction to PASMO fabrication. Then two different designs of PASMO is discussed 
in detail for their biological application. 
Pneumatic actuated soft micromold (PASMO) is constructed by three layers, 
particles’ template, air channel and resistance sheet, from top to bottom, respectively. 
Particles’ templates and air channel are built by Ecoflex® and the resistance sheet is 
composed by Ecoflex-30
®
-cloth. Ecoflex-30
®
 and Ecoflex-30
®
-cloth composite, which 
perform soft and stiff mechanical properties, respectively. Therefore, the expansion of 
particles’ template generates through the actuation of PASMO after injecting air. This 
expansion allow liquid to diffuse into wells of particles’ template and help the extraction 
of collagen particles. The working strategy of PASMO can be classified into four steps: 
filling collagen solution mixed with cells, solidification of collagen solution, and 
expansion of particles’ template after pneumatic actuation, and extraction of collagen 
particles. The collagen particles can be easily duplicated from particles’ template and 
these particles perform highly stability over 60 days. The corresponding collagen fibulas 
density has also been found to be comparable to the one in real tissue environment. The 
high fiber density allows for collagen microstructures to be implanted through syringe 
and remain intact. 
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The deformation of PASMO relies on the design of air channel. In this dissertation, 
we present two different channel designs, straight and circular channel to generate 
different deformation. PASMO within straight channel can perform the one-dimensional 
elongation of particles’ template in order to extract collagen particles. To demonstrate 
the merits of using PASMO contained straight channel for creating cellular environment, 
millimeter scale of collagen particles can be duplicated without any damage during 
extraction.  
MDA-MB-231-GFP cells are encapsulated in these collagen particles in millimeter 
by PASMO devices as modular microenvironment. The cells proliferate continuously 
more than 14 days in this microenvironment. Deformations and contractions of collagen 
particles are simultaneously observed during this period, with cancer cells identified as 
the primary cause of contraction. Collagen particles can also monitor in anti-cancer drug 
response based on the contraction from cells. Moreover, Matrigel
TM
 particles produced 
by PASMO devices can effectively localize the tumor cells at specific location in order 
to develop tumor tissue. Moreover, the tumor volume developed by Matrigel
TM
 particles 
is more uniform than those made by the classical orthotopic method. These results 
indicate that collagen and Matrigel
TM
 microstructures produced by PASMO devices 
possess the potential to improve cancer research. 
Circular channel is another design for PASMO device and the deformation of 
PASMO device belongs to two-dimensional expansion. Therefore, circular channel 
design of PASMO can be used to fabricate smaller or more complicated structure for 
creating collagen microenvironment. Additionally, Circular design can perform larger 
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level of expansion. The expanded area created from circular design presents 6 fold wider 
than the expanded area from straight design. Larger expansion can allow more buffer or 
culture media to diffuse into the expanded area for floating and extracting collagen 
microenvironment from PASMO device. Beta cells encapsulated in collagen micro-disks 
can maintain their basic cellular function and these cells in micro-disk can proliferate 
continuously more than 14 days. Insulin secretion of artificial islet is observed during the 
four-step cycle. When glucose presents but artificial islet is absent in culture media, 
there is no insulin detected in culture media. Once artificial islets are added into the 
solution contained glucose, the insulin can be monitored in culture media. Then, 
artificial islets are shifted to the culture media lacking of glucose and the level of 
secreted insulin would return to zero. Finally, these artificial islets and glucose are 
present in culture media and the secreted insulin can be measured again. According to 
this cyclic test, we can observe artificial islets can maintain and regular their cellular 
function based on the changing of environment.  
PASMO and cPASMO devices provide a controllable process to release 
microparticles gently through adjusting the inner pressure so that cPASMO can apply in 
producing extremely soft and fragile material, like collagen. In this dissertation, collagen 
3D microenvironment can be used observed the cellular response based different stimuli 
from surrounding. Moreover, the confinement of cells at adjusted location not only can 
improve the cellular response but also can reduce the variety of animal experiment. 
Except collagen, we can also use PASMO device to manufacture different materials, 
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especially for extremely soft biomaterial, like alginate, agarose, to create cellular 
microenvironment within specific shape.  
PASMO devices are made of silicone rubber that has elastic responses under large 
deformations and are durable for multiple cycles of deformations. We used a single 
PASMO device more than hundred times by pressurizing and depressurizing them, we 
did not notice any permanent deformations or damages in the devices. Based on this 
observation, we can conclude that PASMO devices are re-usable for several hundred 
cycles.  
Additionally, soft robotics technology will be more and more demanded in 
biomedical fields in the future. As proven in this dissertation, soft robotics is superior to 
handle soft and fragile materials such as cells, tissues, organs due to soft nature. 
Handling such fragile biostructures is critical process in biomedical fields for general 
surgery, laparoscopic surgery, and endoscopy and implantation applications.  
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